MedTrace Logo

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

NCT01669876 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2015-04-30

No results posted yet for this study

Summary

To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Anatabloc(R)

Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day

DIETARY_SUPPLEMENT

Placebo

Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day

Sponsors & Collaborators

  • Roskamp Institute Inc.

    collaborator OTHER

  • Rock Creek Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • A Keegan, MD · Roskamp Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-12-31
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01669876 on ClinicalTrials.gov